Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2016-01-15

FDA Approved: SIMBRINZA — Supplemental Application (Alcon Laboratories, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for SIMBRINZA (brinzolamide/brimonidine tartrate) to update the product labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Simbrinza (brinzolamide/brimonidine)

Snippet

SUPPL AP for SIMBRINZA (BRINZOLAMIDE/BRIMONIDINE TARTRATE)